CD274 and head and neck squamous cell carcinoma: In the HAWK Phase II study, it was administered to individuals with recurrent and/or metastatic HNSCC who had PD-L1 expression in more than 25% of tumor cells after unsuccessful platinum-based chemotherapy [114].